0.1(top 33%)
Impact Factor
0.1(top 33%)
extended IF
29(top 13%)
H-Index
709
authors
11.6K
papers
7.2K
citations
1.8K
citing journals
6K
citing authors

Most Cited Articles of European Urology Supplements

TitleYearCitations
Outcome of GreenLight HPS 120-W Laser Therapy in Specific Patient Populations: Those in Retention, on Anticoagulants, and with Large Prostates (≥ 80ml)200874
Benign Prostatic Hyperplasia and Its Aetiologies200973
Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer200865
Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events200861
Techniques and Training with GreenLight HPS 120-W Laser Therapy of the Prostate: Position Paper200860
The Impact of Tamsulosin Oral Controlled Absorption System (OCAS) on Nocturia and the Quality of Sleep: Preliminary Results of a Pilot Study200557
Nocturia: consequences for sleep and daytime activities andassociated risks200557
Potential Benefits of Muscarinic M3 Receptor Selectivity200255
The physiology of sleep and the impact of ageing200554
Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis201048
Testosterone Associations with Erectile Dysfunction, Diabetes, and the Metabolic Syndrome200747
Staging and Staging Errors in Bladder Cancer201043
Ileal Conduit as the Standard for Urinary Diversion After Radical Cystectomy for Bladder Cancer201043
Transurethral Resection of the Prostate200943
Ureteropelvic Junction Obstruction201242
The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS®)200539
CLINICAL PROOF OF CONCEPT STUDY (BLOSSOM) SHOWS NOVEL β3 ADRENOCEPTOR AGONIST YM178 IS EFFECTIVE AND WELL TOLERATED IN THE TREATMENT OF SYMPTOMS OF OVERACTIVE BLADDER200838
Nocturia: the major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO)200536
Obstructive Bladder Dysfunction: Morphological, Biochemical and Molecular Changes200235
Recurrence, Progression, and Follow-Up in Non–Muscle-Invasive Bladder Cancer200934
Should We Investigate Prostatic Inflammation for the Management of Benign Prostatic Hyperplasia?200933
Improved Classification of Urinary Tract Infection: Future Considerations201630
Bladder Cancer: A Major Public Health Issue200830
Profile of Silodosin201029
Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone?200529